Hints and tips:
...Annaliesa Anderson, Pfizer’s chief scientific officer of vaccine research, said the company would work with the US Food and Drug Administration and other global regulators to secure approvals....
...Annaliesa Anderson, head of vaccine research and development at Pfizer, said it was more important than ever to provide new options to people to protect themselves in the face of rising global rates of Lyme...
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Hagop Kantarjian, an oncologist at the MD Anderson Cancer Center in Texas, said it would be a “national tragedy” if patients could not access the chemotherapies....
...“The composition of the cliff this time around is different in one important respect — biosimilars,” says Tim Anderson, a Bernstein analyst....
...When Pascal Soriot, AstraZeneca’s chief executive, rebuffed a £69.4bn bid from Pfizer in 2014, he said the US group had vastly undervalued the company’s oncology drugs....
...“Why doesn’t Pfizer just buy Bristol-Myers today, given its floundering share price,” asked Timothy Anderson, an analyst at Bernstein, in a recent note to investors, adding that he expected the drugmaker...
...“The company seems likely to leave open its option for a future split up, but more immediately it may continue hunting for M&A targets”, said Tim Anderson, global pharmaceuticals analyst at Sanford Bernstein...
...“While Pfizer is described as having ‘beaten’ other companies in this competitive bid, is this something to be proud of,” asked Tim Anderson, an analyst at Bernstein....
...“Additional deals will likely make the stock go higher, as this is what investors seem to want,” said Timothy Anderson, an analyst at Bernstein Research....
...Tim Anderson, an analyst at Sanford Bernstein, said: “Our belief is that any other deals as big or bigger than this in 2015 are unlikely.”...
...Mr Anderson said Pfizer “seems open” to a deal with a generics manufacturer to bolster its own portfolio of off-patent medicines ahead of a possible future break-up of the group....
...“Every bit of slippage at the company probably does tilt the balance slightly more in favour of a future Pfizer-Astra,” said Tim Anderson, analyst at Bernstein....
...Mr Anderson also highlighted potential competition from similar drugs under development by Eli Lilly and Novartis....
...“AstraZeneca will be a late entrant into the category and it is unclear how the company will compete effectively if there is no differentiation with its approach,” said Tim Anderson, analyst at Bernstein...
...Bill Anderson, head of Goldman Sachs’ defence practice, says that bursts of hostile deals typically come at the beginning and end of any sustained period of M&A activity, as companies move faster to execute...
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...“The whole immuno-oncology area is exploding,” says John LaMattina, former head of research and development for Pfizer....
...Tim Anderson from Bernstein, which rated Pfizer “outperform”, wrote in a research note: “The last big lever management has to pull is to split up the drugs side of the business.”...
...split the remaining drugs side of the business up,” noted Timothy Anderson, pharmaceuticals analyst at Bernstein Research....
...“It is still possible that Pfizer will go the full distance and eventually split up the drugs side of the business, but this is not certain,” said Timothy Anderson, pharmaceuticals analyst at Bernstein Research...
...That mirrored a similar set back only weeks ago for late-stage trials of bapineuzumab, developed by Elan with Johnson Johnson and Pfizer, which have now been abandoned....
International Edition